Proteostasis Therapeutics Inc (PTI):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Proteostasis Therapeutics Inc (PTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9816)・商品コード:DATA904C9816
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:66
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Proteostasis Therapeutics Inc (Proteostasis) is a developer of therapies that discovers and develops therapeutics for the treatment of diseases related to defects in protein folding, trafficking and clearance. The company’s portfolio spans drug candidates for cystic fibrosis, neurodegeneration and protein conformational diseases. Proteostasis employs Disease Relevant Translation platform that combines proteomics, genomics, and functional assays with medicinal chemistry and systems biology to discover novel drugs for disorders such as Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. PTI is headquartered in Cambridge, Massachusetts, the US.

Proteostasis Therapeutics Inc (PTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 12
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 14
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 15
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 16
Partnerships 17
Basilea Pharma Enters into Agreement with Adult Brain Tumor Consortium 17
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 18
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 19
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 20
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 21
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 22
Licensing Agreements 23
Grupo Biotoscana Enters into Licensing Agreement with Basilea Pharma 23
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 24
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 25
Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 26
Dotmatics Enters Into Licensing Agreement With Basilea Pharma For Pre-Clinical Research Informatics 27
Equity Offering 28
Proteostasis Therapeutics Prices Public Offering of Shares for USD74.3 Million 28
Proteostasis Therapeutics to Raise USD50 Million in Public Offering of Shares 30
Proteostasis Therapeutics Withdraws Public Offering of Shares for USD65.6 Million 31
Proteostasis Therapeutics Raises USD46 Million in Public Offering of Shares 33
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 35
Proteostasis Therapeutics Inc – Key Competitors 37
Proteostasis Therapeutics Inc – Key Employees 38
Proteostasis Therapeutics Inc – Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Financial Announcements 40
Mar 14, 2018: Proteostasis Therapeutics Announces Fourth Quarter and Year-End 2017 Financial Results 40
Nov 14, 2017: Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update 43
Mar 30, 2017: Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 45
Corporate Communications 47
Jul 31, 2017: Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer 47
Feb 27, 2017: Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors 48
Product News 49
12/11/2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-801 in Healthy Volunteers and Patients with Cystic Fibrosis 49
Oct 31, 2017: Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs 50
07/31/2017: Proteostasis Therapeutics Provides Update on Development of PTI-428 51
07/31/2017: Proteostasis Therapeutics Provides Update on Development of PTI-801 52
03/12/2018: Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis 53
01/08/2018: Proteostasis Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe 54
Product Approvals 55
Apr 04, 2018: Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis 55
Mar 14, 2018: Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis 56
Jun 23, 2017: Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator 57
Clinical Trials 58
Dec 11, 2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428 in Healthy Volunteers and Patients with Cystic Fibrosis 58
Dec 11, 2017: Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis 59
Jul 31, 2017: Proteostasis Therapeutics Provides Update on Development of PTI-808 60
Jun 29, 2017: Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis 61
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs 63
Jun 07, 2017: Proteostasis Therapeutics Announces Clinical Development Update on Cystic Fibrosis Drug Candidate PTI-801 64
Jun 07, 2017: Proteostasis Therapeutics Announces Update on Phase 1 Trial of PTI-808, CFTR potentiator 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 12
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 14
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 15
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 16
Basilea Pharma Enters into Agreement with Adult Brain Tumor Consortium 17
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 18
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 19
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 20
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 21
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 22
Grupo Biotoscana Enters into Licensing Agreement with Basilea Pharma 23
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 24
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 25
Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 26
Dotmatics Enters Into Licensing Agreement With Basilea Pharma For Pre-Clinical Research Informatics 27
Proteostasis Therapeutics Prices Public Offering of Shares for USD74.3 Million 28
Proteostasis Therapeutics to Raise USD50 Million in Public Offering of Shares 30
Proteostasis Therapeutics Withdraws Public Offering of Shares for USD65.6 Million 31
Proteostasis Therapeutics Raises USD46 Million in Public Offering of Shares 33
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 35
Proteostasis Therapeutics Inc, Key Competitors 37
Proteostasis Therapeutics Inc, Key Employees 38

List of Figures
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Proteostasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Proteostasis Therapeutics Inc (PTI):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9816)販売に関する免責事項を必ずご確認ください。
★調査レポート[Proteostasis Therapeutics Inc (PTI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆